FREEHOLD, NJ--(Marketwired - November 21, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst"), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device would like to update its shareholders on its progress in the international market. The Company has previously announced that it has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Medifirst is pleased to announce that it has been asked to bring its medical staff to Morocco and Dubai to demonstrate its laser technology as part of finalizing its first international sales orders. The Company is optimistic that it will have firm commitments for bulk orders once the demonstrations are completed.
Commented CEO Bruce J. Schoengood, "We are thrilled with the response to our lasers by the international community and we are excited to complete the demonstrations, meet our new vendors, complete and fulfill our purchase orders and finalize our new distribution agreements. We are eager to have our Medical Director and staff show how effective our lasers are in reducing pain." The Company has scheduled the demonstrations in January and anticipates that it will, as previously announced, begin booking sales in Q1 2017. Continued Schoengood, "As we continue to set up international operations, we will also be training licensed technicians to use the laser so as to expedite sales in the Mid-East, Spain and Africa."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.